Swiss Re says GLP-1 drugs could reduce US mortality by up to 6.4%

Reinsurer Swiss Re forecasts that widespread adoption of GLP-1 drugs, like Wegovy and Zepbound, could reduce the annual U.S. death rate by up to 6.4% by 2045, with a minimum reduction of 2.3% under pessimistic assumptions. This projected decline in mortality, also noted for the UK, presents significant implications for the life and medical insurance sectors, potentially reshaping risk models and contributing to longer lifespans. The analysis highlights the transformative impact of these drugs, which are experiencing unprecedented demand and projected annual sales of $150 billion.

Analysis

Research from reinsurer Swiss Re provides a quantitative forecast on the societal impact of GLP-1 drugs, projecting a potential reduction in the U.S. annual death rate by up to 6.4% by 2045 in a high-adoption scenario. Even under pessimistic assumptions, the analysis points to a material 2.3% decline in U.S. mortality, with similar, albeit slightly smaller, reductions anticipated in the UK. This data reinforces the transformative market potential for GLP-1 manufacturers such as Novo Nordisk and Eli Lilly, whose products are already experiencing unprecedented demand and are forecasted by some analysts to generate $150 billion in annual sales by 2030. More significantly, the report highlights a fundamental, long-term shift for the life and medical insurance sectors, as a systemic decrease in mortality and obesity-related morbidity would directly impact actuarial models, underwriting assumptions, and overall industry profitability.

Key Decisions for Investors

• Investors with long-term bullish theses on GLP-1 manufacturers like Eli Lilly and Novo Nordisk can view this report as a key external validation, as reduced mortality projections from a major reinsurer strengthen the case for sustained, large-scale market penetration.
• Consider evaluating positions in life and health insurance companies, as Swiss Re's analysis points to a structural tailwind from reduced mortality and morbidity, which could lower long-term claim costs and improve underwriting margins over the next two decades.
• Monitor GLP-1 drug adoption rates, pricing, and reimbursement coverage, as the significant gap between the pessimistic (2.3%) and optimistic (6.4%) mortality reduction scenarios highlights that the ultimate financial impact is highly dependent on the speed and breadth of market uptake.